TORONTO, Oct. 16, 2014 /PRNewswire/ - SQI Diagnostics Inc.
(TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops
and commercializes proprietary technologies and products for
advanced microarray diagnostics, today announced that it will
present at the Immunogenicity for Biotherapeutics Conference on
Tuesday, October 21, 2014 in
Boston, Massachusetts.
Dr. Jaymie R. Sawyer, SQI
Diagnostics' Vice President of Research and Development, will be
presenting data produced during the development of several
multiplexed assays for its pharma and biotech customers over the
last twelve months. These custom assays were developed to
characterize the pre-clinical and clinical immunogenicity of novel
protein therapeutics. Immunogenicity is an aspect of drug
safety important for biologic drugs.
"We are pleased to be a part of this very prestigious
conference," said Andrew Morris, CEO
of SQI Diagnostics. "This event brings together the world's leading
experts and representatives from all sectors of pharma and
biotechnology drug development and gives us the opportunity to
share our novel multiplexing applications in drug development
testing. Over the past year, we have made significant
progress in our work with our pharma and biotech customers and
believe our unique products will prove to be beneficial
to our customers who are large, global pharmaceutical
companies.
The presentation will be available after October 22 on the corporate website at
http://sqidiagnostics.com/resources.
Please visit our website for our most recent shareholder update
at http://sqidiagnostics.com/about/investors.
For more information, please contact:
Investor Relations Contact:
Andrew Morris
Chief Executive Officer
416.674.9500 ext. 229
amorris@sqidiagnostics.com
Sales and Marketing Contact:
Russ Peloquin
Vice President, Global Commercial Operations
913.484.9022
rpeloquin@sqidiagnostics.com
Forward-looking Information
This press release contains certain forward-looking
statements, including, without limitation, statements containing
the words "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect", "believe", "in the process",
"benefits", "leading to", "possible" "is subject to" and other
similar expressions which constitute "forward-looking information"
within the meaning of applicable securities laws. Forward-looking
statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties
that could cause actual results to differ materially from those
anticipated. These forward-looking statements involve risks and
uncertainties including, but not limited to: our ability to market
and sell our novel multiplexing technologies and detection
platforms; our ability to maintain any technical or product
advantages; our ability to continue to market and sell our
products; SQI's ability to increase customer orders and
manufacturing volumes; adverse changes in general economic
conditions; impact of healthcare reform legislation; and, SQI's
ability to raise additional funds in the future on acceptable terms
or at all. Such statements reflect the current views of the Company
with respect to future events and are subject to certain risks and
uncertainties and other risks detailed from time-to-time in the
Company's ongoing filings with the securities regulatory
authorities, which filings can be found at www.sedar.com. Actual
results, events, and performance may differ materially. Readers are
cautioned not to place undue reliance on these forward-looking
statements. The Company undertakes no obligation to publicly update
or revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by
applicable securities laws.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
SOURCE SQI Diagnostics Inc.